These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 22723853)
1. Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. Derumeaux G; Ernande L; Serusclat A; Servan E; Bruckert E; Rousset H; Senn S; Van Gaal L; Picandet B; Gavini F; Moulin P; PLoS One; 2012; 7(6):e38273. PubMed ID: 22723853 [TBL] [Abstract][Full Text] [Related]
2. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Del Prato S; Erkelens DW; Leutenegger M Acta Diabetol; 2003 Mar; 40(1):20-7. PubMed ID: 12682825 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18 to 34-week, open-label, extension period. Moulin P; André M; Alawi H; Dos Santos LC; Khalid AK; Koev D; Moore R; Serban V; Picandet B; Francillard M Diabetes Metab; 2009 Feb; 35(1):64-70. PubMed ID: 19150252 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study. Moulin P; Andre M; Alawi H; dos Santos LC; Khalid AK; Koev D; Moore R; Serban V; Picandet B; Francillard M Diabetes Care; 2006 Mar; 29(3):515-20. PubMed ID: 16505498 [TBL] [Abstract][Full Text] [Related]
5. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study. Maréchaux S; Jeu A; Jobic Y; Ederhy S; Donal E; Réant P; Abouth S; Arnasteen E; Boulanger J; Ennezat PV; Garban T; Szymanski C; Tribouilloy C Arch Cardiovasc Dis; 2013; 106(6-7):349-56. PubMed ID: 23876809 [TBL] [Abstract][Full Text] [Related]
6. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. Roger P; Auclair J; Drain P J Diabetes Complications; 1999; 13(2):62-7. PubMed ID: 10432168 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas. Stucci N; de Gregoris P; Lavielle R; Tomasi F J Diabetes Complications; 1996; 10(5):267-73. PubMed ID: 8887015 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958 [TBL] [Abstract][Full Text] [Related]
9. Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease. Boudes A; Lavoute C; Avierinos JF; Le Dolley Y; Villacampa C; Salem A; Loundou AD; Michel N; Renard S; Habib G Eur J Echocardiogr; 2011 Sep; 12(9):688-95. PubMed ID: 21810827 [TBL] [Abstract][Full Text] [Related]
10. Adverse effects of benfluorex on heart valves and pulmonary circulation. Szymanski C; Andréjak M; Peltier M; Maréchaux S; Tribouilloy C Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):679-86. PubMed ID: 24817577 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of benfluorex in type II diabetic patients on diet regimen alone. Velussi M; Monte AD; Cernigoi AM J Diabetes Complications; 1996; 10(5):261-6. PubMed ID: 8887014 [TBL] [Abstract][Full Text] [Related]
12. Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study. Tribouilloy C; Rusinaru D; Maréchaux S; Jeu A; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Ennezat PV; Garban T; Jobic Y Circulation; 2012 Dec; 126(24):2852-8. PubMed ID: 23143159 [TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration criteria for the diagnosis of drug-induced valvular heart disease in patients previously exposed to benfluorex: a prospective multicentre study. Maréchaux S; Rusinaru D; Jobic Y; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Garban T; Ennezat PV; Jeu A; Szymanski C; Tribouilloy C Eur Heart J Cardiovasc Imaging; 2015 Feb; 16(2):158-65. PubMed ID: 25368209 [TBL] [Abstract][Full Text] [Related]
14. Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Le Ven F; Tribouilloy C; Habib G; Gueffet JP; Maréchaux S; Eicher JC; Blanchard-Lemoine B; Rousseau J; Hénon P; Jobic Y; Etienne Y Eur J Echocardiogr; 2011 Apr; 12(4):265-71. PubMed ID: 21193484 [TBL] [Abstract][Full Text] [Related]
15. Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study. Tribouilloy C; Maréchaux S; Jobic Y; Jeu A; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Garban T; Ennezat PV; Andréjak M; Rusinaru D Eur Heart J; 2013 Dec; 34(46):3580-7. PubMed ID: 24014218 [TBL] [Abstract][Full Text] [Related]
16. Mitral and aortic valvular disease associated with benfluorex use. Etienne Y; Jobic Y; Frachon I; Fatemi M; Castellant P; Quintin-Roué I J Heart Valve Dis; 2011 May; 20(3):348-50. PubMed ID: 21714428 [TBL] [Abstract][Full Text] [Related]
17. Restrictive organic mitral regurgitation associated with benfluorex therapy. Tribouilloy C; Rusinaru D; Henon P; Tribouilloy L; Leleu F; Andréjak M; Sevestre H; Peltier M; Caus T Eur J Echocardiogr; 2010 Aug; 11(7):614-21. PubMed ID: 20237052 [TBL] [Abstract][Full Text] [Related]
18. Cumulative incidence of cardiac surgery associated with exposure to benfluorex: A retrospective analysis based on compensation claims data. Farrington P; Lellinger S Stat Med; 2024 Jun; 43(13):2641-2654. PubMed ID: 38693582 [TBL] [Abstract][Full Text] [Related]